about
Towards a vaccine against Plasmodium vivax malariaPromising functional readouts of immunity in a blood-stage malaria vaccine trialThe global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impactMerozoite surface proteins in red blood cell invasion, immunity and vaccines against malariaAntibodies to reticulocyte binding protein-like homologue 4 inhibit invasion of Plasmodium falciparum into human erythrocytesStructure-Activity Studies of β-Hairpin Peptide Inhibitors of the Plasmodium falciparum AMA1-RON2 InteractionExported proteins required for virulence and rigidity of Plasmodium falciparum-infected human erythrocytesMalaria parasite signal peptide peptidase is an ER-resident protease required for growth but not for invasionIntermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trialConformational dynamics and antigenicity in the disordered malaria antigen merozoite surface protein 2A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720Skeleton-binding protein 1 functions at the parasitophorous vacuole membrane to traffic PfEMP1 to the Plasmodium falciparum-infected erythrocyte surfacePTEX is an essential nexus for protein export in malaria parasitesComplement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand.Sir2 paralogues cooperate to regulate virulence genes and antigenic variation in Plasmodium falciparumInsights into the Immunological Properties of Intrinsically Disordered Malaria Proteins Using Proteome Scale Predictions.Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum.Prevention of postpartum haemorrhage by community-based auxiliary midwives in hard-to-reach areas of Myanmar: a qualitative inquiry into acceptability and feasibility of task shifting.Antibody to P. falciparum in pregnancy varies with intermittent preventive treatment regime and bed net use.Plasmodium vivax adherence to placental glycosaminoglycans.Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria.Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum.Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adultsThe relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.Using an improved phagocytosis assay to evaluate the effect of HIV on specific antibodies to pregnancy-associated malaria.Antibody Responses to Plasmodium falciparum and Plasmodium vivax and Prospective Risk of Plasmodium spp. Infection Postpartum.Cross-reactive surface epitopes on chondroitin sulfate A-adherent Plasmodium falciparum-infected erythrocytes are associated with transcription of var2csa.Intermittent preventive treatment to reduce the burden of malaria in children: new evidence on integration and deliveryEvaluation of the antigenic diversity of placenta-binding Plasmodium falciparum variants and the antibody repertoire among pregnant women.Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes.Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assaysPlacental malaria induces variant-specific antibodies of the cytophilic subtypes immunoglobulin G1 (IgG1) and IgG3 that correlate with adhesion inhibitory activity.Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development.Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.Selective accumulation of mature asexual stages of Plasmodium falciparum-infected erythrocytes in the placenta.Minimal association of common red blood cell polymorphisms with Plasmodium falciparum infection and uncomplicated malaria in Papua New Guinean school children.Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates.High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria.Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum.Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.
P50
Q21090139-2A7785A4-37BE-4E61-A2AF-FA0ED6FF7D0BQ24814446-8EE28326-AFDD-407E-90E8-5B558DEE5AF6Q26247068-DDE35516-B5AD-4F17-B98A-E6DA19AAF3A3Q26772878-945A5A3D-F9CB-4979-8F27-E6E18098A1B9Q27230046-A5E346D5-64C5-468C-B8A7-E78AACDA0E51Q27719709-6CD18C83-1A6D-4CF8-803B-9D4C2D9962C3Q27973501-B1686116-B7B2-4EB8-BFE5-4290F1250554Q27976475-7AE2EDAC-5F50-4193-8D82-960A66D018A4Q28481649-159D3E58-1BAB-4591-BFC5-2B210CEFFE3AQ28543881-5D895110-1008-4A04-9C6B-E1F647C39D4EQ28744696-33AA979E-4DEF-4DCD-82E2-D2D69B294B53Q30038747-7CF4EAF5-FCFE-4F1A-A5B6-759D8BA6F231Q30042849-C496721A-D798-435E-9A5B-78F197587E77Q30043671-33598C20-271F-43E0-8680-EDE4C70EE2E9Q30046035-1064B97E-7599-4B2D-A278-7FCB8DAFAE9AQ30380793-5BB67795-1D95-478D-A739-0E905C12C6D1Q30658099-80189E3D-7F39-41C0-9B0E-25274313DDBEQ30851479-09B7AD13-85BA-4533-BC56-05511973EF53Q31047525-748D3890-10C8-46D8-A6DA-34A0660265B2Q31056451-BE55BAE1-D2C8-4475-A749-626465552BBCQ31169310-5F286C90-7D1D-4956-8C0E-4395582B383AQ33380204-7691BF17-C8DC-4828-B73A-F2E32BE57E7AQ33380213-BD178A75-FE35-4E40-95E7-0B04A7C16047Q33526349-2FDD44D8-2814-460F-BCB5-93EE9F8BF60EQ33593182-8CB2AF1C-4FF5-4AE1-B40D-722CDD53B731Q33636850-3DE1860E-CD28-4E57-B872-BB223780C6C0Q33769127-1C0F28E3-4BE1-452F-8411-D85980D0F650Q33815505-4858F48A-FE25-47A4-B659-046DBBD0CEE7Q33826049-C3F315C7-E25B-4417-B5BF-530682938351Q33826076-E0F74179-E7AD-40C9-8BF1-5FB3DA21DD76Q33939788-41EE9223-9EEE-47F2-B01F-530854C0F328Q34034060-68DC5405-EBCF-4616-856F-DE8B20312F74Q34069682-032C7C63-4043-4E68-AD61-E429124932FAQ34081745-1AD31C96-9E2C-461B-9D15-DBE2495415B3Q34132871-674735FE-DFE2-47D2-8559-790D247E183DQ34160113-7F981285-7773-4EBB-A047-961DA5B5697DQ34161839-C1F5D8D4-8604-45E2-AC4B-BD8F9A0C687CQ34171724-F6E4E6C8-B5D4-4123-AE59-F2B0B04F44AEQ34316582-E24FCA11-E228-4380-9915-5B090C12EC32Q34416904-1F0C7046-0549-4185-B00C-CA7437DDEB14
P50
description
Australian biomedical researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James Beeson
@en
James G Beeson
@ast
James G Beeson
@nl
type
label
James Beeson
@en
James G Beeson
@ast
James G Beeson
@nl
altLabel
James G Beeson
@en
James G. Beeson
@en
prefLabel
James Beeson
@en
James G Beeson
@ast
James G Beeson
@nl
P106
P108
P21
P31
P496
0000-0002-1018-7898